Compass Pathways (STU:5Y6) ROCE % : -49.70% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Compass Pathways ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Compass Pathways's annualized ROCE % for the quarter that ended in Mar. 2024 was -49.70%.

Compass Pathways ROCE % Historical Data

The historical data trend for Compass Pathways's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways ROCE % Chart

Compass Pathways Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-113.59

-45.80

-30.55

-40.52

-52.08

Compass Pathways Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-55.72	-66.79	-53.99	-45.42	-49.70

Compass Pathways ROCE % Calculation

Compass Pathways's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-105.895	/	( ( (186.246 - 14.723)	+	(253.08 - 17.977) )	/ 2 )
	=	-105.895	/	( (171.523	+	235.103)	/ 2 )
	=	-105.895	/	203.313
	=	-52.08 %

Compass Pathways's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-124.632	/	( ( (253.08 - 17.977)	+	(284.274 - 17.85) )	/ 2 )
	=	-124.632	/	( ( 235.103	+	266.424 )	/ 2 )
	=	-124.632	/	250.7635
	=	-49.70 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Compass Pathways (STU:5Y6) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Compass Pathways ROCE % Related Terms

Thank you for viewing the detailed overview of Compass Pathways's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Compass Pathways (STU:5Y6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (STU:5Y6) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CMPS:USA 5Y6:Germany

Address

33 Broadwick Street, London, GBR, W1F 0DQ

Website

https://www.compasspathways.com

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Compass Pathways (STU:5Y6) Headlines

No Headlines